Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.
Blauvelt A, Gordon KB, Langley RG, Branigan PJ, Chen Y, Miller M, Han C, Fakharzadeh S, Muñoz-Elías EJ, Armstrong AW. Blauvelt A, et al. Among authors: han c. J Invest Dermatol. 2024 Dec;144(12):2816-2819.e2. doi: 10.1016/j.jid.2024.05.020. Epub 2024 Jun 25. J Invest Dermatol. 2024. PMID: 38936766 Free article. No abstract available.
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Langley RG, et al. Among authors: han c. J Am Acad Dermatol. 2010 Sep;63(3):457-65. doi: 10.1016/j.jaad.2009.09.014. Epub 2010 May 11. J Am Acad Dermatol. 2010. PMID: 20462664 Clinical Trial.
Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM. Papp KA, et al. Among authors: han c. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1515-1522. doi: 10.1111/jdv.14910. Epub 2018 Apr 10. J Eur Acad Dermatol Venereol. 2018. PMID: 29512196 Free PMC article. Clinical Trial.
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K. Gordon KB, et al. Among authors: han c. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012. Epub 2018 Jul 18. J Eur Acad Dermatol Venereol. 2018. PMID: 29706008 Clinical Trial.
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA. Armstrong AW, et al. Among authors: han c. Am J Clin Dermatol. 2019 Feb;20(1):155-164. doi: 10.1007/s40257-018-0396-z. Am J Clin Dermatol. 2019. PMID: 30417277 Free PMC article. Clinical Trial.
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
Reich K, Foley P, Han C, McElligott S, Muser E, Li N, Armstrong AW. Reich K, et al. Among authors: han c. J Dermatolog Treat. 2020 Sep;31(6):617-623. doi: 10.1080/09546634.2019.1628172. Epub 2019 Jul 15. J Dermatolog Treat. 2020. PMID: 31305186 Free article. Clinical Trial.
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A. Reich K, et al. Among authors: han c. J Am Acad Dermatol. 2020 Apr;82(4):936-945. doi: 10.1016/j.jaad.2019.11.040. Epub 2019 Dec 4. J Am Acad Dermatol. 2020. PMID: 31809827 Free article. Clinical Trial.
10,028 results
You have reached the last available page of results. Please see the User Guide for more information.